GSK 관리

관리 기준 확인 4/4

GSK CEO는 Emma Walmsley, Apr2017 에 임명되었습니다 의 임기는 8.08 년입니다. 총 연간 보상은 £ 10.56M, 12.9% 로 구성됩니다. 12.9% 급여 및 87.1% 보너스(회사 주식 및 옵션 포함). 는 $ 46.64M 가치에 해당하는 회사 주식의 0.06% 직접 소유합니다. 46.64M. 경영진과 이사회의 평균 재임 기간은 각각 6.2 년과 3.1 년입니다.

주요 정보

Emma Walmsley

최고 경영자

UK£10.6m

총 보상

CEO 급여 비율	12.91%
CEO 임기	8.1yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	6.2yrs
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Emma Walmsley 의 보수는 GSK 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2025	n/a	n/a	UK£3b
Dec 31 2024	UK£11m	UK£1m	UK£3b
Sep 30 2024	n/a	n/a	UK£3b
Jun 30 2024	n/a	n/a	UK£4b
Mar 31 2024	n/a	n/a	UK£4b
Dec 31 2023	UK£13m	UK£1m	UK£5b
Sep 30 2023	n/a	n/a	UK£6b
Jun 30 2023	n/a	n/a	UK£5b
Mar 31 2023	n/a	n/a	UK£4b
Dec 31 2022	UK£8m	UK£1m	UK£4b
Sep 30 2022	n/a	n/a	UK£3b
Jun 30 2022	n/a	n/a	UK£4b
Mar 31 2022	n/a	n/a	UK£4b
Dec 31 2021	UK£8m	UK£1m	UK£3b
Sep 30 2021	n/a	n/a	UK£4b
Jun 30 2021	n/a	n/a	UK£4b
Mar 31 2021	n/a	n/a	UK£5b
Dec 31 2020	UK£7m	UK£1m	UK£5b
Sep 30 2020	n/a	n/a	UK£6b
Jun 30 2020	n/a	n/a	UK£7b
Mar 31 2020	n/a	n/a	UK£5b
Dec 31 2019	UK£8m	UK£1m	UK£5b
Sep 30 2019	n/a	n/a	UK£5b
Jun 30 2019	n/a	n/a	UK£4b
Mar 31 2019	n/a	n/a	UK£4b
Dec 31 2018	UK£6m	UK£1m	UK£4b

보상 대 시장: Emma 의 총 보상 ($USD 14.29M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 14.24M ).

보상과 수익: Emma 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Emma Walmsley (55 yo)

8.1yrs

테뉴어

UK£10,559,000

보상

Dame Emma Natasha Walmsley serves as an Independent Director of Microsoft Corp. since December 4, 2019. She serves as Chief Executive Officer of GSK plc since April 1, 2017. Dame Walmsley served as the Chi...

리더십 팀

이름	위치	테뉴어	보상	소유권
Emma Walmsley	CEO & Director	8.1yrs	UK£10.56m	0.060% $ 46.6m
Julie Brown	CFO & Executive Director	2.1yrs	UK£4.17m	0.0042% $ 3.3m
Jesse Goodman	Scientific & Medical Expert	no data	UK£182.11k	0.00076% $ 594.9k
Shobie Ramakrishnan	Chief Digital & Technology Officer	4.3yrs	데이터 없음	데이터 없음
Tony Wood	Chief Scientific Officer and Head of R&D	2.8yrs	데이터 없음	데이터 없음
James Ford	Senior VP & Group General Counsel of Legal & Compliance	6.8yrs	데이터 없음	데이터 없음
Sally Jackson	Senior VP of Global Communications & CEO Office	6.2yrs	데이터 없음	데이터 없음
David Redfern	President of Corporate Development	no data	데이터 없음	데이터 없음
Diana Conrad	Chief People Officer	6.1yrs	데이터 없음	데이터 없음
Philip Thomson	President of Global Affairs	8.1yrs	데이터 없음	0.0068% $ 5.3m
Luke Miels	Chief Commercial Officer	7.7yrs	데이터 없음	데이터 없음
Regis Simard	President of Global Supply Chain	no data	데이터 없음	데이터 없음

6.2yrs

평균 재임 기간

56.5yo

평균 연령

경험이 풍부한 관리: GSK 의 관리팀은 노련하고 경험 (평균 재직 기간 6.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Emma Walmsley	CEO & Director	8.3yrs	UK£10.56m	0.060% $ 46.6m
Julie Brown	CFO & Executive Director	2yrs	UK£4.17m	0.0042% $ 3.3m
Jonathan Symonds	Non-Executive Chairman	5.7yrs	UK£781.00k	0.0021% $ 1.6m
Vishal Sikka	Independent Non-Executive Director	2.8yrs	UK£137.38k	0.00045% $ 352.2k
Hal Barron	Non-Executive Director	7.3yrs	UK£369.02k	0.033% $ 25.9m
Harry Dietz	Independent Non-Executive Director	3.3yrs	UK£219.65k	0.00019% $ 148.7k
Anne Beal	Independent Non-Executive Director	4yrs	UK£203.68k	0.00020% $ 156.6k
Wendy Mira Becker	Independent Non-Executive Director	1.6yrs	UK£157.00k	0.000070% $ 54.8k
Charles Bancroft	Senior Independent Non-Executive Director	5yrs	UK£265.98k	0.0016% $ 1.3m
Gavin Screaton	Independent Non-Executive Director	no data	데이터 없음	0.00021% $ 164.4k
Tsun-Huei Lee	Scientific & Medical Expert and Independent Non-Executive Director	1.2yrs	UK£132.59k	0.000050% $ 39.1k
Elizabeth Anderson	Independent Non-Executive Director	2.7yrs	UK£164.54k	0.00012% $ 93.9k

3.1yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: GSK 의 이사회는 경험(평균 재직 기간 3.1 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/23 11:38
장 마감 주가	2025/05/23 00:00
수익	2025/03/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

GSK plc 69 애널리스트 중 19 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

GSK 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

GSK plc, Annual General Meeting, May 07, 2025

GSK plc Announces Board and Committee Changes

Recent updates

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK Reported Strong Earnings, So I Reiterate My Strong Buy

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.

Us Food and Drug Administration Accepts GSK Plc's Shingrix New Prefilled Syringe Presentation of Shingrix for the Prevention of Shingles (Herpes Zoster)

GSK Gets FDA Breakthrough Therapy Designation for GSK5764227

Gsk Plc's B7-H3-Targeted Antibody-Drug Conjugate, Gsk'227, Receives US Fda Breakthrough Therapy Designation in Late-Line Relapsed or Refractory Osteosarcoma

GSK plc's Nucala (Mepolizumab) Approves in China for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps

GSK plc Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

GSK plc's Jemperli (dostarlimab) Receives US FDA Breakthrough Therapy Designation for Locally Advanced dMMR/MSI-H Rectal Cancer

GSK Is Doing The Right Things But Can't Catch A Break - Rating Downgrade

GSK plc Announces Results from Planned Interim Analysis of the DREAMM-7 Trial Evaluating Belantamab Mafodotin in Combination with Bortezomib Plus Dexamethasone

GSK plc Announces Blenrep Combination China Filing Acceptance

Gsk Plc's Fully Liquid Menveo Meningococcal Vaccine Approves by European Commission

Linerixibat Shows Positive Phase III Results in Cholestatic Pruritus (Relentless Itch) in Primary Biliary Cholangitis (Pbc)

GSK plc Announces Overall Survival Results for Blenrep

GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy'

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK's Q2 Success Amid Challenges: What Investors Need To Know

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc (LSE:GSK) completed the acquisition of BELLUS Health Inc. (TSX:BLU).

CEO 보상 분석

CEO

리더십 팀

이사회 구성원